Jyong Biotech
MENS
17 hedge funds and large institutions have $974K invested in Jyong Biotech in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 6 closing their positions.
0.31% less ownership
Funds ownership: 0.91% → 0.6% (-0.31%)
11% less funds holding
Funds holding: 19 → 17 (-2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
64% less capital invested
Capital invested by funds: $2.73M → $974K (-$1.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Personalized Indexing Management
Oakland,
California
|
+$34.1K |
| 2 |
HF
HRT Financial
New York
|
+$28.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$16.9K |
| 4 |
Barclays
London,
United Kingdom
|
+$4.03K |
| 5 |
CUAMC
China Universal Asset Management Company
Shanghai,
China
|
+$1.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$275K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$265K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$91.6K |
| 4 |
Millennium Management
New York
|
-$62.8K |
| 5 |
Man Group
London,
United Kingdom
|
-$56.2K |
MENS Hedge Fund Activity: Q1 2026 in Review
17 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Jyong Biotech (MENS) for Q1 2026, worth a combined $974K — down 64% from $2.73M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MENS and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Personalized Indexing Management, opening a new position worth an estimated $34.1K. The largest seller was Jane Street, exiting entirely with an estimated $275K sold.
- 17 institutional investors held Jyong Biotech (MENS) as of Q1 2026, down from 19 in Q4 2025.
- Funds reported $974K of Jyong Biotech stock for Q1 2026, down 64% quarter-over-quarter.
- 4 funds opened new Jyong Biotech positions in Q1 2026 and 6 closed out, a net change of -2 holders.
- The largest Jyong Biotech buyer in Q1 2026 was Vanguard Personalized Indexing Management, an estimated $34.1K added.
- The largest Jyong Biotech seller in Q1 2026 was Jane Street, an estimated $275K sold.
Based on aggregated 13F filings for Q1 2026.